Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Huang James

(Last) (First) (Middle)
8030 EL RIO ST.


(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/22/2022 A 80,000 A $0.00 188,333 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $0.82 06/22/2022 A 100,000 (1) 06/21/2032 Common Stock 100,000 $0.00 100,000 D
Explanation of Responses:
1. The option vests in twelve equal monthly installments beginning on July 13, 2022.
Exhibit List - Exhibit 24 - Power of Attorney
/s/ Melinda Lackey, Attorney-in-Fact 06/24/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                                                                   Exhibit 24

                              Power of Attorney

     Know all by these presents, that the undersigned hereby makes,
constitutes and appoints each of Melinda Lackey and Michael Wong, or either of
them acting singly, and with full power of substitution and re-substitution,
the undersigned's true and lawful attorney-in-fact (each of such persons and
their substitutes being referred to herein as the "Attorney-in-Fact"), with
full power to act for the undersigned and in the undersigned's name, place and
stead, in any and all capacities, to:

     1.  Prepare, execute, and submit to the Securities and Exchange Commission
         ("SEC") a Form ID, including amendments thereto, and any other
         documents necessary or appropriate to obtain codes and passwords
         enabling the undersigned to make electronic filings with the SEC of
         reports required or considered by the Attorney-in-Fact to be advisable
         under Section 13 or Section 16 of the Securities Exchange Act of 1934
         (the "Exchange Act") or any rule or regulation of the SEC;

     2.  Prepare, execute and submit to the SEC, Ziopharm Oncology, Inc.
         (including any successor or assign, the "Company"), and/or any
         national securities exchange on which the Company's securities are
         listed any and all reports (including any amendments thereto) the
         undersigned is required to file with the SEC, or which the Attorney-
         in-Fact considers it advisable to file with the SEC, under Section 13
         or Section 16 of the Exchange Act or any rule or regulation
         thereunder, or under Rule 144 under the Securities Act of 1933 ("Rule
         144"), with respect to the any security of the Company, including
         Forms 3, 4 and 5, Schedules 13D and 13G, and Forms 144; and

     3.  Obtain, as the undersigned's representative and on the undersigned's
         behalf, information regarding transactions in the Company's equity
         securities from any third party, including the Company and any
         brokers, dealers, employee benefit plan administrators and trustees,
         and the undersigned hereby authorizes any such third party to release
         any such information to the Attorney-in-Fact.

     The undersigned acknowledges that:

         a)  This Power of Attorney authorizes, but does not require, the
             Attorney-in-Fact to act in his or her discretion on information
             provided to such Attorney-in-Fact without independent verification
             of such information;

         b)  Any documents prepared or executed by the Attorney-in-Fact on
             behalf of the undersigned pursuant to this Power of Attorney will
             be in such form and will contain such information as the Attorney-
             in-Fact, in his or her discretion, deems necessary or desirable;

         c)  Neither the Company nor the Attorney-in-Fact assumes any liability
             for the undersigned's responsibility to comply with the
             requirements of Section 13 or Section 16 of the Exchange Act or
             Rule 144, any liability of the undersigned for any failure to
             comply with such requirements, or any liability of the undersigned
             for disgorgement of profits under Section 16(b) of the Exchange
             Act; and

         d)  This Power of Attorney does not relieve the undersigned from
             responsibility for compliance with the undersigned's obligations
             under Section 13 or Section 16 of the Exchange Act, including,
             without limitation, the reporting requirements under Section 13 or
             Section 16 of the Exchange Act.

     The undersigned hereby grants to the Attorney-in-Fact full power and
authority to do and perform each and every act and thing requisite, necessary
or advisable to be done in connection with the foregoing, as fully, to all
intents and purposes, as the undersigned might or could do in person, hereby
ratifying and confirming all that the Attorney-in-Fact, or his or her
substitute or substitutes, shall lawfully do or cause to be done by authority
of this Power of Attorney.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G
or Forms 144 with respect to the undersigned's holdings of and transactions in
securities of the Company, unless earlier revoked by the undersigned in a
signed writing delivered to the Attorney-in-Fact. This Power of Attorney
revokes all previous powers of attorney with respect to the subject matter of
this Power of Attorney.

     The signature may be delivered via facsimile, electronic mail
(including any electronic signature covered by the U.S. federal ESIGN Act of
2000, Uniform Electronic Transactions Act, the Electronic Signatures and
Records Act or other applicable law, e.g., or other
transmission method and any signature so delivered shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes.

     IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney
as of January 20th, 2022

                                   James Huang

                                   /s/ James Huang